Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia

Leukemia

Volumn 30, Issue 8, 2016, Pages 1753-1756

  Alvarez Twose, I ^a   Martinez Barranco P ^b   Gotlib, J ^c   Garcia Montero A ^d   Morgado, J M ^a   Jara Acevedo, M ^d   Merker, J D ^c   Penalver F J ^b   Matito, A ^a   Hou, Y ^c   Sanchez Munoz L ^a   Mayado, A ^d   Mollejo, M ^a   Escribano, L ^d   Orfao, A ^d  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CD33 ANTIGEN; CLADRIBINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DEXCHLORPHENIRAMINE; DNA; GEMTUZUMAB OZOGAMICIN; HEMOGLOBIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYUREA; IMATINIB; METHYLPREDNISOLONE; MIDOSTAURIN; MONTELUKAST; NUCLEOTIDE; PARACETAMOL; PEGINTERFERON; PEGINTERFERON ALPHA2B; RANITIDINE; TRYPTASE; AMINOGLYCOSIDE; GEMTUZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ANAPHYLAXIS; ANTIGEN EXPRESSION; ARM; ASPIRATION; BLOOD CELL COUNT; BONE MARROW BIOPSY; CASE REPORT; CELL INFILTRATION; CORTICOSTEROID THERAPY; CYTOLOGY; CYTOPENIA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DUODENUM PERFORATION; ENZYME BLOOD LEVEL; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; GENE SEQUENCE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; IN VITRO STUDY; INFUSION; LAPAROTOMY; LETTER; LOW DRUG DOSE; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOMA; MEDIATOR RELEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL; PREMEDICATION; PRIORITY JOURNAL; REFRACTORY MAST CELL LEUKEMIA; REMISSION; SURGICAL INFECTION; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; PROCEDURES; SALVAGE THERAPY; TUMOR RECURRENCE;

AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FEMALE; HUMANS; LEUKEMIA, MAST-CELL; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY;

EID: 84959553201     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.30     Document Type: Letter

References (15)

1. Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization (WHO) Classification of Tumours, vol. 1. IARC Press: Lyon, France, 2001, pp 291-302
2. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-625
3. Valent P, Sotlar K, Sperr WR, Escribano L, Yavuz S, Reiter A, et al. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol 2014; 25: 1691-1700
4. Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011; 86: 531-535
5. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotar K, Hermine O, et al. Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. Blood 2014; 124: 636
6. Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol 2014; 32: 3264-3274
7. Krauth MT, Bohm A, Agis H, Sonneck K, Samorapoompichit P, Florian S, et al. Effects of the CD33-Targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. Exp Hematol 2007; 35: 108-116
8. Valent P, Akin C, Escribano L, Födinger M, Hatmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453
9. van Der Velden VH, Te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001; 97: 3197-3204
10. Orfao A, Escribano L, Villarrubia J, Velasco JL, Cerveró C, Ciudad J, et al. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration. Am J Pathol 1996; 149: 1493-1499
11. Amadori S, Suciu S, Selleslag D, Stasi R, Alimena G, Baila L, et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol 2010; 149: 376-382
12. Jeong DK, Fauman K, Ross C, Akin C, Mody R. Successful treatment of systemic mastocytosis associated with AML-M2, t (8: 21) in a child using MRC-based AML chemotherapy along with gemtuzumab. J Allergy Clin Immunol 2007; 119(Suppl 1): S207 (abstract 814)
13. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635-641
14. Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, et al. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 2013; 121: 2393-2401
15. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074